Together, these results demonstrate the target-dependent activity of MLN8237 against GTML/Trp53KI/KI medulloblastomas and suggest clinical benefit in treating relapsed P53-MYC medulloblastoma with agents that target aberrant expression of MYCN. Here, MYC is linked to medulloblastoma.